Rutgeerts P - Search Results

1

Mucosal expression by B7-positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel disease.

Peetermans WE, D'Haens GR, Ceuppens JL, Rutgeerts P, Geboes K. Peetermans WE, et al. Among authors: rutgeerts p. Gastroenterology. 1995 Jan;108(1):75-82. doi: 10.1016/0016-5085(95)90010-1. Gastroenterology. 1995. PMID: 7528700

2

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.

Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P. Suenaert P, et al. Among authors: rutgeerts p. Am J Gastroenterol. 2002 Aug;97(8):2000-4. doi: 10.1111/j.1572-0241.2002.05914.x. Am J Gastroenterol. 2002. PMID: 12190167

3

A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.

Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. Van Assche G, et al. Among authors: rutgeerts p. Am J Gastroenterol. 2003 Feb;98(2):369-76. doi: 10.1111/j.1572-0241.2003.07239.x. Am J Gastroenterol. 2003. PMID: 12591057

4

The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence.

Ferrante M, de Hertogh G, Hlavaty T, D'Haens G, Penninckx F, D'Hoore A, Vermeire S, Rutgeerts P, Geboes K, van Assche G. Ferrante M, et al. Among authors: rutgeerts p. Gastroenterology. 2006 May;130(6):1595-606. doi: 10.1053/j.gastro.2006.02.025. Gastroenterology. 2006. PMID: 16697723

Patients with this feature had a higher endoscopic recurrence (Rutgeerts score >/=2) at 3 months (75% vs 41%; odds ratio, 4.36; 95% confidence interval, 1.44-13.23; P = .008) and at 1 year (93% vs 59%; odds ratio, 9.80; 95% confidence interval, 1.04-92.70; P …

Patients with this feature had a higher endoscopic recurrence (Rutgeerts score >/=2) at 3 months (75% vs 41%; odds ratio, 4.36; 95 …

5

Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).

Ferrante M, D'Haens G, Rutgeerts P, Vermeire S, Van Assche G. Ferrante M, et al. Among authors: rutgeerts p. Curr Gastroenterol Rep. 2009 Dec;11(6):504-8. doi: 10.1007/s11894-009-0076-5. Curr Gastroenterol Rep. 2009. PMID: 19903427 Review.

6

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Baert FJ, et al. Among authors: rutgeerts pj. Gastroenterology. 1999 Jan;116(1):22-8. doi: 10.1016/s0016-5085(99)70224-6. Gastroenterology. 1999. PMID: 9869598 Clinical Trial.

7

Infectious agents in inflammatory bowel disease.

Rutgeerts P, Peeters M, Geboes K, Vantrappen G. Rutgeerts P, et al. Endoscopy. 1992 Aug;24(6):565-7. doi: 10.1055/s-2007-1010546. Endoscopy. 1992. PMID: 1396366 No abstract available.

8

Endoscopy in inflammatory bowel disease.

Rutgeerts P, Vantrappen G, Geboes K. Rutgeerts P, et al. Scand J Gastroenterol Suppl. 1989;170:12-5; discussion 16-9. doi: 10.3109/00365528909091341. Scand J Gastroenterol Suppl. 1989. PMID: 2617183

9

CD44v6 and CD44v3 variants in inflammatory bowel disease.

Geboes K, Rutgeerts P. Geboes K, et al. Among authors: rutgeerts p. Lancet. 1995 May 13;345(8959):1191-2. doi: 10.1016/s0140-6736(95)91985-6. Lancet. 1995. PMID: 7537839 No abstract available.

10

Appendectomy protects against ulcerative colitis.

Rutgeerts P, D'Haens G, Hiele M, Geboes K, Vantrappen G. Rutgeerts P, et al. Gastroenterology. 1994 May;106(5):1251-3. doi: 10.1016/0016-5085(94)90016-7. Gastroenterology. 1994. PMID: 8174886

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

727 results

Search Page

Filters